



Iressa

Iressa (Gefitinib) is indicated as monotherapy for the treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) AFTER failure of a platinum-based AND docetaxol chemotherapies. Initial therapy <= 14 days of therapy

If patient is concurrently taking a CYP3A4 Inducer (i.e. rifampin or phenytoin), the dosage may need increased to 500 milligrams daily if there is absence of adverse events

Patients on Coumadin (warfarin) should be monitored regularly for changes in their INR or prothrombin times

Member Information

Relationship (Circle)

Subscriber Spouse Dependent

Name _____

Enrollment / Cardholder ID _____

Group / Plan _____

Birth date _____

Address: _____

City State Zip _____

Gender (Circle)

Male Female

AGE: _____

Practitioner Information

Name _____

Agent / Contact Name _____

Specialty _____

Office / Clinic Name _____

Address _____

City State Zip _____

Phone () - _____

Fax () - _____

Email @ _____

Failed platinum-based AND docetaxol chemotherapies?

Yes No (circle)

Requested Drug / Pharmaceutical

Iressa - Gefitinib

Strength / Dose

Duration of Therapy (Expected)

Condition / Diagnosis Related - Reason for Request

Type of Request (Circle)

One-Time On-Going

Clinical Drug / Lab History Pertinent to Request

Contact Pharmacy? Y N

Pharmacy Phone Number

Formulary Alternative(s) Attempted YES NO (Circle)

Practitioner Signature